Home / Isis Clinical Trial Update

Isis Clinical Trial Update

Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) announced the identification of a drug development candidate, IONIS-DMPKRx, designed to treat Myotonic Dystrophy Type 1 (DM1), which they plan to advance into human clinical trials next year. Ionis Pharmaceutical's DM1 antisense program is being developed to correct the underlying genetic defect that causes DM1.

In addition, Ionis Pharmaceuticals is working closely with the Biogen Idec team on designing the clinical program and selecting and optimizing biomarkers to provide us with robust measures of activity once the clinical trials are started. Isis expects to start the drug toxicology program later this fall in preparation for human clinical studies next year. 

09/09/2013

 

 

 

Partners

© Myotonic Dystrophy Foundation. All rights reserved.